Mounjaro
strong$550-$1,086/mo cash price
Identical molecule (tirzepatide) labeled for type 2 diabetes instead of chronic weight management.
Relevant only when patient has a diabetes diagnosis and coverage attached.
View Mounjaro on GLP1ZoomAlternatives
Zepbound alternatives — what to ask your prescriber
A printable summary of therapeutic alternatives to Zepbound (tirzepatide), the current FDA generic-status outlook, and the questions to bring to your prescriber visit.
These are therapeutic alternatives, NOT FDA-approved generic substitutes. Therapeutic alternatives are different medications in a similar drug class. A true generic requires FDA ANDA approval — and as of 2026, only liraglutide (Victoza / Saxenda) has an FDA-approved generic among GLP-1 medications. Only your prescriber can recommend or approve a switch.
Generic Zepbound: not available until ~~2036-2039
Active ingredient
tirzepatide
FDA generic status
Not yet approved
Patent / NDA holder
Eli Lilly
Estimated generic year
~2036-2039
Tirzepatide composition-of-matter patent extends past 2036; pen-injector device patents add additional years. As a newer molecule than semaglutide, generic timing is later. No FDA-approved generic.
Therapeutic alternatives, by category
Equivalence strength reflects shared mechanism of action plus the depth of head-to-head clinical evidence. Costs are US cash-price estimates and vary widely by pharmacy, insurance, and manufacturer copay programs.
Same drug class, different molecule
FDA-approved generic liraglutide
Compounded (NOT FDA-approved as finished drug)
Compounded semaglutide
moderate$150-$350/mo cash price
Compounded by 503A/503B pharmacies. NOT FDA-approved as a finished drug; no FDA bioequivalence testing. Legal compounding window narrowed after semaglutide left the FDA shortage list in 2025.
A prescriber must determine that a compounded version is clinically necessary; not therapeutically substitutable like a true generic.
View Compounded semaglutide on GLP1ZoomCompounded tirzepatide
moderate$250-$500/mo cash price
Compounded by 503A/503B pharmacies. NOT FDA-approved as a finished drug. Legal compounding window for tirzepatide narrowed after it left the FDA shortage list in 2024.
Limited supply and legal exposure for compounders post-shortage delisting.
Different drug class (non-GLP-1)
Qsymia (phentermine/topiramate)
weak$95-$220/mo cash price
Oral once-daily. ~8-10% mean weight loss — well below tirzepatide.
Stimulant; contraindicated in pregnancy, glaucoma, hyperthyroidism.
Non-pharmaceutical / lifestyle
Structured lifestyle + RD-supervised nutrition
weak$0-$250/mo cash price
No medication side-effect risk. Average weight loss with intensive lifestyle programs is 5-10% of body weight over 12 months — meaningful for some patients, well below GLP-1 efficacy for others.
Often combined with — not replacing — GLP-1 therapy; insurance may cover RD visits under obesity-care benefits.
Talk to a prescriber
Bring this summary to a visit, or connect with a telehealth GLP-1 prescriber who can review your insurance, dosing history, and tolerability before recommending any switch.
FAQ
- Is there a generic version of Zepbound?
- No. There is no FDA-approved generic tirzepatide as of 2026. Tirzepatide composition-of-matter patent extends past 2036; pen-injector device patents add additional years. As a newer molecule than semaglutide, generic timing is later. No FDA-approved generic.
- When will generic Zepbound be available?
- Estimated US generic availability: ~2036-2039. This is an estimate based on USPTO Orange Book exclusivity and composition-of-matter patent expiry. Tirzepatide composition-of-matter patent extends past 2036; pen-injector device patents add additional years. As a newer molecule than semaglutide, generic timing is later. No FDA-approved generic.
- Is compounded tirzepatide the same as a generic?
- No. Compounded products are prepared by licensed compounding pharmacies and are NOT FDA-approved as finished drugs. They have not undergone FDA bioequivalence testing and are not legally substitutable the way a true ANDA-approved generic would be.
- Can I switch from Zepbound to one of these alternatives on my own?
- No. Switching GLP-1 medications requires a prescriber's clinical judgment about your indication, dose-titration history, side-effect tolerance, and insurance coverage. The alternatives listed here are options to DISCUSS with your prescriber — not recommendations.
Compare GLP-1 telehealth providers
SponsoredPartner offers first — we earn a commission from those — then ranked by our editorial score. Visit a partner to check current pricing and eligibility — we compare providers, we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
- Sesame Care· from $208/moTop ratedTelehealth · online visit
- SkinnyRx· from $199/moCompounded not offered in AL, LA, MS — check before startingTelehealth · online visitCompounded · not FDA-approved
- Enhance MD· price shown after their intakeNo lab work to startRestricted in AL, AR, GA, HI, LA, MS, MO, ND, SC, TN, WV — check before startingTelehealth · online visitCompounded · not FDA-approved
- HealthRX· from $165/moLowest starting priceon the 12-month plan, $1,188 billed upfrontTelehealth · online visitCompounded · not FDA-approved